Refanezumab

Refanezumab is a monoclonal antibody designed for the treatment of migraine. It is developed by Teva Pharmaceuticals and is currently in the clinical trial phase. Refanezumab works by blocking the calcitonin gene-related peptide receptor (CGRP), a protein that plays a key role in migraine attacks.

Mechanism of Action

Refanezumab is a monoclonal antibody that targets and blocks the CGRP receptor. CGRP is a neuropeptide that is released during a migraine attack and is believed to play a key role in the transmission of pain. By blocking the CGRP receptor, refanezumab prevents the activation of this pathway and reduces the frequency and severity of migraine attacks.

Clinical Trials

Refanezumab is currently in Phase III clinical trials. In a Phase IIb study, refanezumab demonstrated a significant reduction in the number of migraine days per month compared to placebo. The most common side effects reported were injection site reactions.

Development

Refanezumab is being developed by Teva Pharmaceuticals, a global pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals.

See Also

• Monoclonal antibodies
• Migraine
• Teva Pharmaceuticals
• Clinical trial
• Calcitonin gene-related peptide receptor